Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

May 2020 | 100 pages | ID: A1BA2C627F19EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Anaplastic lymphoma kinase-Non Small Cell Lung Cancer (ALK-NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted ALK NSCLCepidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Understanding

Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.

There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma..

There are several genetic mutations identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence response to targeted therapy. There are several mutations associated with NSCLC but the most common are EGFR, KRAS, ROS-1, BRAF, C-Met, PD-L1 expression and others. Among all the mutations ALK mutation accounted for approximately 4% of the total cases of NSCLC.

ALK-positive mutation was discovered in 2007. ALK-positive lung cancers harbor a gene rearrangement referred to as the EML4-ALK fusion gene, compose a subset of tumors for which medical treatment has expanded rapidly (along with survival) in the past few years. An ALK mutation is diagnosed by molecular profiling of a sample of the tumor. It’s important in doing this testing that an adequate supply of tissue from either a lung biopsy or lung cancer surgery is obtained. Researchers are also looking at ways to determine if an ALK mutation is present before genetic testing is done, or could substitute for genetic testing.

Epidemiology Perspective by DelveInsight

The ALK NSCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The ALK NSCLC epidemiology data are studied through ALK NSCLC possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted Anaplastic lymphoma kinase-Non Small Cell Lung Cancer epidemiology [segmented as Total Incidence of NSCLC Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total ALK-NSCLC cases, and Treated Patient Pool of ALK-NSCLC] scenario of Anaplastic lymphoma kinase-Non Small Cell Lung Cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Detailed Epidemiology Segmentation

• Total incident population of NSCLC in the 7MM was assessed to be 4,84,726 in 2017.
• Total incident population of ALK NSCLC in the 7MM was assessed to be 22,197 in 2017.
• The total incident cases of ALK NSCLC in the United States were found to be 8,449 in 2017 which is expected grow during the study period, i.e., 2017–2030.
• In case of EU-5, Germany hold upto around 29% of the EU-5 Patient population. Japan accounts upto 5,000 ALK-Positive cases in 2017.

Scope of the Report

• The ALK NSCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The ALK NSCLC Report and Model provide an overview of the risk factors and global trends of ALK NSCLC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
• The report provides insight about the historical and forecasted patient pool of ALK NSCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of ALK NSCLC.
• The report provides the segmentation of the ALK NSCLC epidemiology by total Incidence of NSCLC in the 7MM.
• The report provides the segmentation of the ALK NSCLC epidemiology by total diagnosed cases of NSCLC patients by Stages in the 7MM.
• The report provides the segmentation of the ALK NSCLC epidemiology by Histology in the 7MM.
• The report provides the segmentation of the ALK NSCLC epidemiology by Treated Patient Pool of ALK NSCLC in the 7MM.

Report Highlights

• 11-Year Forecast of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer epidemiology
• 7MM Coverage
• Total Incident Cases of Non-Small Cell Lung Cancer
• Incident Cases according to segmentation: Histology, ALK-NSCLC
• Treated cases of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over ALK NSCLC scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase-Non Small Cell Lung Cancer ?
• What are the key findings pertaining to the Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer?

Reasons to buy

The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market
• Quantify patient populations in the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anaplastic lymphoma kinase-Non Small Cell Lung Cancer therapeutics in each of the markets covered
• Understand the magnitude of Anaplastic lymphoma kinase-Non Small Cell Lung Cancer population by its severity
• The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Total Incident cases of ALK NSCLC in the United States was assessed to be 8,449 in 2017, and are expected to increase during the study period. Among the European 5 countries, Germany had Incident population of ALK NSCLC. On the other hand, Spain had the lowest incident cases of ALK NSCLC in 2017.

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF ALK-NSCLC

3. SWOT ANALYSIS OF ALK-NSCLC

4. ALK-NSCLC: MARKET OVERVIEW AT A GLANCE

4.1. Total Incidence Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Incidence Share (%) Distribution of NSCLC in 2030: By Country

5. ALK-NON-SMALL CELL LUNG CANCER (NSCLC): DISEASE BACKGROUND AND OVERVIEW

5.1. Introduction
  5.1.1. Cellular Classification of NSCLC
  5.1.2. Signs and Symptoms of NSCLC
  5.1.3. Risk Factors of Lung Cancer
  5.1.4. Causes of NSCLC
  5.1.5. Disease Biology: NSCLC

6. DIAGNOSIS OF NSCLC

6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System

7. EPIDEMIOLOGY AND PATIENT POPULATION

7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
  7.3.1. Total Incident cases of NSCLC patients in the 7MM
  7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
  7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
  7.4.1. Total Incident cases of NSCLC patients in the United States
  7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
  7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
  7.4.4. Total ALK NSCLC cases in the United States
  7.4.5. Total ALK NSCLC Treated patient Pool in the United States

8. EU-5 EPIDEMIOLOGY

8.1. Germany
  8.1.1. Total Incident cases of NSCLC patients in Germany
  8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
  8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
  8.1.4. Total ALK NSCLC cases in Germany
  8.1.5. Total ALK NSCLC Treated patient Pool in Germany
8.2. France
  8.2.1. Total Incident cases of NSCLC patients in France
  8.2.2. Total Incident cases of NSCLC patients by Histology in France
  8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
  8.2.4. Total ALK NSCLC cases in France
  8.2.5. Total ALK NSCLC Treated patient Pool in France
8.3. Italy
  8.3.1. Total Incident cases of NSCLC patients in Italy
  8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
  8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
  8.3.4. Total ALK NSCLC cases in Italy
  8.3.5. Total ALK NSCLC Treated patient Pool in Italy
8.4. Spain
  8.4.1. Total Incident cases of NSCLC patients in Spain
  8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
  8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
  8.4.4. Total ALK NSCLC cases in Spain
  8.4.5. Total ALK NSCLC Treated patient Pool in Spain
8.5. The United Kingdom
  8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
  8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
  8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
  8.5.4. Total ALK NSCLC cases in the United Kingdom
  8.5.5. Total ALK NSCLC Treated patient Pool in the United Kingdom

9. JAPAN EPIDEMIOLOGY

9.1. Japan
  9.1.1. Total Incident cases of NSCLC patients in Japan
  9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
  9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
  9.1.4. Total ALK NSCLC cases in Japan
  9.1.5. Total ALK NSCLC Treated patient Pool in Japan

10. APPENDIX

10.1. Bibliography
10.2. Report Methodology

11. DELVEINSIGHT CAPABILITIES

12. DISCLAIMER

13. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1 Summary of Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total ALK NSCLC cases in the United States
Table 10 Total ALK NSCLC Treated patient Pool in the United States
Table 11 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 12 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 13 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 14 Total ALK NSCLC cases in Germany
Table 15 Total ALK NSCLC Treated patient Pool in Germany
Table 16 Total Incident cases of NSCLC patients in France (2017–2030)
Table 17 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 18 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 19 Total ALK NSCLC cases in France
Table 20 Total ALK NSCLC Treated patient Pool in France
Table 21 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 23 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 24 Total ALK NSCLC cases in Italy
Table 25 Total ALK NSCLC Treated patient Pool in Italy
Table 26 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 29 Total ALK NSCLC cases in Spain
Table 30 Total ALK NSCLC Treated patient Pool in Spain
Table 31 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 32 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 33 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 34 Total ALK NSCLC cases in the United Kingdom
Table 35 Total ALK NSCLC Treated patient Pool in the United Kingdom
Table 36 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 37 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 38 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 39 Total ALK NSCLC cases in Japan
Table 40 Total ALK NSCLC Treated patient Pool in Japan

List Of Figures

LIST OF FIGURES

Figure 1 ALK NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total ALK NSCLC cases in the United States
Figure 22 Total ALK NSCLC Treated patient Pool in the United States
Figure 23 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 24 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 25 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 26 Total ALK NSCLC cases in Germany
Figure 27 Total ALK NSCLC Treated patient Pool in Germany
Figure 28 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 29 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 30 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 31 Total ALK NSCLC cases in France
Figure 32 Total ALK NSCLC Treated patient Pool in France
Figure 33 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 35 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 36 Total ALK NSCLC cases in Italy
Figure 37 Total ALK NSCLC Treated patient Pool in Italy
Figure 38 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 41 Total ALK NSCLC cases in Spain
Figure 42 Total ALK NSCLC Treated patient Pool in Spain
Figure 43 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 44 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 45 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 46 Total ALK NSCLC cases in the United Kingdom
Figure 47 Total ALK NSCLC Treated patient Pool in the United Kingdom
Figure 48 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 49 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 50 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 51 Total ALK NSCLC cases in Japan
Figure 52 Total ALK NSCLC Treated patient Pool in Japan